Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

Faivre‐Finn, Corinne; Vicente, David; Kurata, Takayasu; Planchard, David; Paz‐Ares, Luis; Vansteenkiste, Johan; R. Spigel, David; Chiara Garassino, Marina; Reck, Martin; Senan, Suresh; Naidoo, Jarushka; Rimner, Andreas; Wu, Yi‐Long; E. Gray, Jhanelle; Özgüroğlu, Mustafa; Hyeong Lee, Ki; Chul Cho, Byoung; Kato, Terufumi; de Wit, Maike; Newton, Michael; Wang, Lu; Thiyagarajah, Piruntha; Antonia, Scott

doi:10.1016/j.jtho.2020.12.015

Public

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

Published in Journal of Thoracic Oncology • Jan 19, 2021

Authors:

Corinne Faivre‐Finn

David Vicente

Takayasu Kurata

Abstract

INTRODUCTION: In the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable, stage III NSCLC without disease progression after concurrent chemoradiotherapy, consolidative durvalumab was associated with significant improvements in the primary end points of overall survival (OS) (haza...

Subject

Medicine

Durvalumab

Hazard ratio

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!